goodrx holdings inc. - GDRX
GDRX
Close Chg Chg %
4.66 -0.19 -4.08%
Pre-Market
4.47
-0.19 (4.08%)
Volume: 1.12M
Last Updated:
Mar 13, 2025, 4:00 PM EDT
Company Overview: goodrx holdings inc. - GDRX
GDRX Key Data
| Open $4.63 | Day Range 4.37 - 4.63 |
| 52 Week Range 4.09 - 9.26 | Market Cap $1.79B |
| Shares Outstanding 383.61M | Public Float 88.68M |
| Beta 1.26 | Rev. Per Employee N/A |
| P/E Ratio 109.09 | EPS $0.04 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.97M |
GDRX Performance
| 1 Week | -3.04% | ||
| 1 Month | -11.31% | ||
| 3 Months | -5.10% | ||
| 1 Year | -35.31% | ||
| 5 Years | N/A |
GDRX Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
19
Full Ratings ➔
About goodrx holdings inc. - GDRX
GoodRx Holdings, Inc. engages in the business of a consumer-focused digital healthcare platform. The firm offers consumers free access to transparent and lower prices for brand and generic medications, affordable and convenient medical provider consultations via telehealth, and comprehensive healthcare research and information. The company was founded by Trevor Bezdek and Douglas Joseph Hirsch in September 2011 and is headquartered in Santa Monica, CA.
GDRX At a Glance
GoodRx Holdings, Inc.
2701 Olympic Boulevard
Santa Monica, California 90404
| Phone | 1-855-268-2822 | Revenue | 792.32M | |
| Industry | Internet Software/Services | Net Income | 16.39M | |
| Sector | Technology Services | 2024 Sales Growth | 5.606% | |
| Fiscal Year-end | 12 / 2025 | Employees | 738 | |
| View SEC Filings |
GDRX Valuation
| P/E Current | 109.091 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 111.244 |
| Price to Sales Ratio | 2.302 |
| Price to Book Ratio | 2.456 |
| Price to Cash Flow Ratio | 9.917 |
| Enterprise Value to EBITDA | 12.08 |
| Enterprise Value to Sales | 2.422 |
| Total Debt to Enterprise Value | 0.283 |
GDRX Efficiency
| Revenue/Employee | 1,073,609.756 |
| Income Per Employee | 22,208.672 |
| Receivables Turnover | 4.926 |
| Total Asset Turnover | 0.532 |
GDRX Liquidity
| Current Ratio | 5.321 |
| Quick Ratio | 5.321 |
| Cash Ratio | 3.619 |
GDRX Profitability
| Gross Margin | 85.138 |
| Operating Margin | 11.27 |
| Pretax Margin | 3.971 |
| Net Margin | 2.069 |
| Return on Assets | 1.101 |
| Return on Equity | 2.205 |
| Return on Total Capital | 1.293 |
| Return on Invested Capital | 1.207 |
GDRX Capital Structure
| Total Debt to Total Equity | 74.985 |
| Total Debt to Total Capital | 42.852 |
| Total Debt to Total Assets | 39.147 |
| Long-Term Debt to Equity | 73.518 |
| Long-Term Debt to Total Capital | 42.014 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Goodrx Holdings Inc. - GDRX
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 745.42M | 766.55M | 750.26M | 792.32M | |
Sales Growth
| +35.36% | +2.83% | -2.12% | +5.61% | |
Cost of Goods Sold (COGS) incl D&A
| 81.25M | 118.81M | 170.09M | 117.75M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 37.64M | 57.53M | 111.77M | 69.54M | |
Depreciation
| 7.10M | 7.95M | 8.90M | 4.50M | |
Amortization of Intangibles
| 30.54M | 49.58M | 102.87M | 65.04M | |
COGS Growth
| +69.22% | +46.22% | +43.16% | -30.77% | |
Gross Income
| 664.17M | 647.74M | 580.17M | 674.57M | |
Gross Income Growth
| +32.12% | -2.47% | -10.43% | +16.27% | |
Gross Profit Margin
| +89.10% | +84.50% | +77.33% | +85.14% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 636.47M | 610.58M | 528.80M | 585.28M | |
Research & Development
| 125.86M | 138.88M | 133.44M | 123.75M | |
Other SG&A
| 510.61M | 471.70M | 395.36M | 461.53M | |
SGA Growth
| -17.35% | -4.07% | -13.39% | +10.68% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 14.30M | 46.83M | 77.03M | 25.52M | |
EBIT after Unusual Expense
| 13.41M | (9.67M) | (25.65M) | 63.77M | |
Non Operating Income/Expense
| 59.00K | 20.68M | 26.81M | 20.61M | |
Non-Operating Interest Income
| 59.00K | 9.27M | 32.17M | 23.27M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 23.64M | 34.24M | 56.73M | 52.92M | |
Interest Expense Growth
| -15.30% | +44.84% | +65.66% | -6.71% | |
Gross Interest Expense
| 23.64M | 34.24M | 56.73M | 52.92M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (10.18M) | (23.23M) | (55.57M) | 31.46M | |
Pretax Income Growth
| +96.65% | -128.27% | -139.21% | +156.61% | |
Pretax Margin
| -1.37% | -3.03% | -7.41% | +3.97% | |
Income Tax
| 15.08M | 9.60M | (46.70M) | 15.07M | |
Income Tax - Current - Domestic
| 2.17M | 10.09M | 18.86M | 26.98M | |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| 12.91M | (497.00K) | (65.56M) | (11.91M) | |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (25.25M) | (32.83M) | (8.87M) | 16.39M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (25.25M) | (32.83M) | (8.87M) | 16.39M | |
Net Income Growth
| +91.40% | -29.99% | +72.99% | +284.82% | |
Net Margin Growth
| -3.39% | -4.28% | -1.18% | +2.07% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (25.25M) | (32.83M) | (8.87M) | 16.39M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (25.25M) | (32.83M) | (8.87M) | 16.39M | |
EPS (Basic)
| -0.063 | -0.0795 | -0.0216 | 0.0425 | |
EPS (Basic) Growth
| +91.60% | -26.19% | +72.83% | +296.76% | |
Basic Shares Outstanding
| 400.56M | 412.86M | 410.31M | 385.74M | |
EPS (Diluted)
| -0.063 | -0.0795 | -0.0216 | 0.0418 | |
EPS (Diluted) Growth
| +91.60% | -26.19% | +72.83% | +293.52% | |
Diluted Shares Outstanding
| 400.56M | 412.86M | 410.31M | 392.17M | |
EBITDA
| 65.34M | 94.69M | 163.15M | 158.83M | |
EBITDA Growth
| +126.73% | +44.90% | +72.30% | -2.65% | |
EBITDA Margin
| +8.77% | +12.35% | +21.75% | +20.05% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 6.706 | |
| Number of Ratings | 19 | Current Quarters Estimate | 0.094 | |
| FY Report Date | 03 / 2025 | Current Year's Estimate | 0.386 | |
| Last Quarter’s Earnings | 0.09 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 0.34 | Next Fiscal Year Estimate | 0.467 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 13 | 13 | 14 | 12 |
| Mean Estimate | 0.09 | 0.10 | 0.39 | 0.47 |
| High Estimates | 0.10 | 0.11 | 0.45 | 0.50 |
| Low Estimate | 0.08 | 0.09 | 0.23 | 0.39 |
| Coefficient of Variance | 6.68 | 6.47 | 13.58 | 7.14 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 10 | 10 | 10 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 8 | 8 | 8 |
| UNDERWEIGHT | 1 | 1 | 1 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Goodrx Holdings Inc. - GDRX
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Goodrx Holdings Inc. - GDRX
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 11, 2025 | Romin Nabiey Chief Accounting Officer | 105,449 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $4.61 per share | 486,119.89 |
| Mar 11, 2025 | Romin Nabiey Chief Accounting Officer | 109,640 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 11, 2025 | Romin Nabiey Chief Accounting Officer | 106,874 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $4.61 per share | 492,689.14 |
| Mar 11, 2025 | Romin Nabiey Chief Accounting Officer | 107,682 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 11, 2025 | Romin Nabiey Chief Accounting Officer | 26,787 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 11, 2025 | Romin Nabiey Chief Accounting Officer | 61,205 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 6, 2025 | Christopher A. McGinnis See Remarks | 1,096,937 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Wendy Barnes See Remarks; Director | 1,842,374 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Wendy Barnes See Remarks; Director | 2,828,232 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Christopher A. McGinnis See Remarks | 716,479 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Wendy Barnes See Remarks; Director | 409,416 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 24, 2025 | Scott W. Wagner Director | 94,182 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 24, 2025 | Scott W. Wagner Director | 317,850 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 24, 2025 | Scott W. Wagner Director | 298,633 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 6, 2025 | Ronald Earl Bruehlman Director | 32,284 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 6, 2025 | Douglas Joseph Hirsch Director | 154,338 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jul 11, 2024 | Julie Marie B. Bradley Director | 126,117 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jul 11, 2024 | Kelly J. Kennedy Director | 30,862 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jul 11, 2024 | Ian T. Clark Director | 51,745 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jul 11, 2024 | Ian T. Clark Director | 25,852 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |